

DESCRIPTION


| | |
|---------------------------|--|
| Species Reactivity | Mouse |
| Specificity | Detects mouse CTLA-4 in direct ELISAs and Western blots. In direct ELISAs, this antibody does not cross-react with recombinant mouse (rm) CD28, recombinant human CTLA-4, rmlCOS, or rmpD-1. |
| Source | Monoclonal Rat IgG _{2A} Clone # 63828 |
| Purification | Protein A or G purified from hybridoma culture supernatant |
| Immunogen | Mouse myeloma cell line NS0-derived recombinant mouse CTLA-4 Ala36-Phe161 Accession # XP_001479180 |
| Endotoxin Level | <0.10 EU per 1 µg of the antibody by the LAL method. |
| Formulation | Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS. |

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

| | Recommended Concentration | Sample |
|-----------------------|------------------------------|---|
| Western Blot | 1 µg/mL | Recombinant Mouse CTLA-4 Fc Chimera (Catalog # 434-CT) under non-reducing conditions only |
| Flow Cytometry | 2.5 µg/10 ⁶ cells | Mouse splenocytes treated with ConA |
| Neutralization | | Measured by its ability to neutralize CTLA-4 inhibition of B7-1/CD80-induced IL-2 secretion in the Jurkat human acute T cell leukemia cell line. Linsley, P. <i>et al.</i> (1990) Proc. Natl. Acad. Sci. USA 87 :5031. The Neutralization Dose (ND ₅₀) is typically 2.5-10 µg/mL in the presence of 1 µg/mL Recombinant Mouse CTLA-4 Fc Chimera, 3 µg/mL Recombinant Human B7-1/CD80 Fc Chimera, and 10 µg/mL PHA. |

DATA



PREPARATION AND STORAGE

| | |
|--------------------------------|--|
| Reconstitution | Reconstitute at 0.5 mg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution. |

BACKGROUND

CTLA-4 and CD28, together with their ligands B7-1 and B7-2, constitute one of the dominant costimulatory pathways that regulate T and B cell responses. CTLA-4 and CD28 are structurally homologous molecules that are members of the immunoglobulin (Ig) gene superfamily. Both CTLA-4 and CD28 are composed of a single Ig V-like extracellular domain, a transmembrane domain and an intracellular domain. CTLA-4 and CD28 are both expressed on the cell surface as disulfide-linked homodimers or as monomers. The genes encoding these two molecules are closely linked on human chromosome 2. CTLA-4 was originally identified as a gene that was specifically expressed by cytotoxic T lymphocytes. However, CTLA-4 transcripts have since been found in both Th1 and Th2, and CD4⁺ and CD8⁺ T cell clones. Whereas, CD28 expression is constitutive on the surfaces of 95% of CD4⁺ T cells and 50% of CD8⁺ T cells and is down regulated upon T cell activation, CTLA-4 expression is upregulated rapidly following T cell activation and peaks approximately 24 hours following activation. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with 20-100-fold higher affinity than CD28. The physiological role of CTLA-4 in T cell costimulation is currently being studied. Recombinant human or mouse CTLA-4/Fc chimera preparations produced at R&D Systems have been shown to bind both B7-1 and B7-2 with high affinity and to inhibit CD28 signalling competitively.

References:

1. Lenschow, D.J. *et al.* (1996) *Annu. Rev. Immunol.* **14**:233.
2. Hathcock, K.S. and R.J. Hodes (1996) *Advances in Immunol.* **62**:131.
3. Ward, S.G. (1996) *Biochem. J.* **318**:361.